Hill, Rachel C.
Caplan, Avrom S.
Elewski, Boni
Gold, Jeremy A. W.
Lockhart, Shawn R.
Smith, Dallas J.
Lipner, Shari R. http://orcid.org/0000-0001-5913-9304
Article History
Accepted: 23 January 2024
First Online: 18 March 2024
Declarations
:
: No sources of funding were used to assist in the preparation of this review.
: This work has not been previously published.
: Rachel C. Hill, Avrom S. Caplan, Boni Elewski, Jeremy A.W. Gold, Shawn R. Lockhart, Dallas J. Smith, and Shari R. Lipner have no conflicts of interest to declare.
: Shari R. Lipner has served as a consultant for Ortho-Dermatologics, Eli Lilly, Moberg Pharmaceuticals, and BelleTorus Corporation.
: No ethical approval was required as this was a review study.
: Patient consent was not required as this was a review study.
: Data/code sharing are not applicable to this article as no datasets or code were generated and/or analyzed during the current study.
: Not applicable.
: Shari R. Lipner, MD, PhD.
: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
: RCH, ASC, BE, JAWG, SRLo, DJS, and SRLi have made substantial contributions to all aspects of the work. All authors read and approved the final version of the manuscript.